High serum levels of soluble CD44 variant isoform v5 and ovarian cancer outcomes
Author Information
Author(s): AG Zeimet, M Widschwendter, M Uhl-Steidi, E Muller-Holzner, G Daxenbichier, C Marth, 0 Dapunt
Primary Institution: University Hospital, Innsbruck, Austria
Hypothesis
High pretreatment serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcomes in ovarian cancer patients.
Conclusion
The study found that high levels of soluble CD44 variant isoform v5 in serum are linked to better survival rates in ovarian cancer patients.
Supporting Evidence
- Patients with CD44v5 levels above 35 ng/ml had a significantly better survival rate.
- High CD44v5 levels were inversely correlated with indicators of immune system activation.
- Lower CD44v5 levels were associated with higher CA-125 levels, a tumor marker.
Takeaway
If a patient with ovarian cancer has high levels of a specific protein called CD44v5 in their blood, they are more likely to do well.
Methodology
The study measured serum levels of soluble CD44 isoforms in ovarian cancer patients and compared them with healthy controls, using enzyme-linked immunosorbent assays.
Limitations
The study was retrospective and excluded patients with immune system disorders or previous cancer treatments.
Participant Demographics
Patients aged 23-88 years, median age 64, with advanced epithelial ovarian cancer.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website